GS
ACLX

Gilead Sciences’s Arcellx ACLX Stock Holding History

Gilead Sciences’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$772M Hold
6,720,803
– – 36.44% 1
2025
Q4 		$438M Hold
6,720,803
– – 22.64% 3
2025
Q3 		$552M Hold
6,720,803
– – 30.8% 2
2025
Q2 		$443M Hold
6,720,803
– – 34.57% 2
2025
Q1 		$441M Hold
6,720,803
– – 37.32% 1
2024
Q4 		$515M Buy
+6,720,803
New +$581M 33.23% 1

Other funds holding ACLX

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Gilead Sciences's ACLX Position: Q1 2026 in Review

Gilead Sciences held its Arcellx (ACLX) position steady in Q1 2026 at 6,720,803 shares worth $772M. The position accounts for 36.44% of the portfolio, ranked #1.

Gilead Sciences first reported a position in ACLX in Q4 2024 and has held it in 6 quarters since. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • Gilead Sciences held 6,720,803 shares of Arcellx worth $772M as of Q1 2026.
  • Gilead Sciences left its Arcellx share count unchanged in Q1 2026.
  • Arcellx made up 36.44% of Gilead Sciences's portfolio in Q1 2026, its #1 holding.
  • Gilead Sciences first reported a position in Arcellx in Q4 2024 and has held it in 6 quarters since.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Gilead Sciences's 13F filing for Q1 2026, filed 8 May 2026.